The Philippine Economic Zone Authority (PEZA) opened 2026 with solid investment momentum, approving 18 new projects worth P12.86 billion during its first Board meeting of the year.
The Philippine Economic Zone Authority (PEZA) is accelerating the rollout of digital permits, visa processing, and customs integration, translating the Marcos administration’s “Big Bold Reforms” agenda into concrete, on-the-ground improvements for investors.
Zen LifeSciences Inc. is making a major P1.2-billion investment in local pharmaceutical manufacturing, announcing plans to build a state-of-the-art production facility at the Luisita Industrial Park–Special Economic Zone in Tarlac.
The Philippine Economic Zone Authority (PEZA) is betting big on the information-technology business process management (IT-BPM) sector to fuel the next wave of job creation across the country’s ecozones through 2028.
Japanese firm Ubukata Philippine Electric Corporation is reinforcing the Philippines’ ambition to move up the manufacturing value chain, as it sets up export-oriented production of safety switches and electrical control equipment in Batangas.
The Bangko Sentral ng Pilipinas (BSP) has maintained the 3.0-percent monthly ceiling on finance charges for unpaid credit card balances while raising the limits on installment add-on rates and cash advance processing fees.
SM Hotels and Convention Centers (SMHCC) is adding a premium rooftop events venue at Conrad Manila, broadening its offerings for private celebrations and corporate gatherings as it builds out the Mall of Asia Complex as a destination for meetings and events.
PLDT Inc. has until February 13, 2027, to submit its delayed 2024 and 2025 annual financial reports to avoid possible suspension and delisting proceedings on the New York Stock Exchange (NYSE), following the withdrawal of its external auditor’s opinions on the two sets of financial statements.
Metrobank Chief Economist Nicholas Mapa has been named the top analyst at The Asset Benchmark Research Awards, clinching the Best Individual Sellside Research title.